Carfilzomib
Treatment for Multiple Myeloma
Typical Dosage: 20-56 mg/m² IV, typically twice weekly in 28-day cycles
Effectiveness
90%
Safety Score
48%
Clinical Trials
219
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
48
DangerousModerateSafe
Treatment Details
Dosage Range
20-56 mg/m² IV, typically twice weekly in 28-day cycles
Time to Effect
1-2 months
Treatment Duration
6-18 months
Evidence Quality
HIGHConfidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200,000
Monitoring:$10,000
Side Effect Mgmt:$15,000
Total Annual:$225,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
2
Outcome-Based Costs
Cost per Responder
$264,706
Cost per Remission
$450,000
Comparison vs Bortezomib + Dexamethasone
Cost Difference
+$80,000/year
More expensive
QALY Difference
+0.80 QALYs
Better outcomes
Dominance
No dominance
Carfilzomib Outcomes
for Multiple Myeloma
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+85%
Remission Rate
+50%
Common Side Effects
Hypertension
+25%
Cardiac Events (heart failure, ischemia)
+10%
Thrombocytopenia
+40%
Fatigue
+40%
Renal Toxicity
+15%
Active Clinical Trials
3 active trials recruiting for Carfilzomib in Multiple Myeloma
Home Treatment With Carfilzomib in Patients With Multiple Myeloma
NCT05620238RECRUITING
12 participants
OBSERVATIONAL
Odense, Denmark
Started: Dec 15, 2022
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
NCT05651932RECRUITINGPHASE1
125 participants
INTERVENTIONAL
San Francisco, United States +21 more
Started: Feb 22, 2023
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
NCT03815279ENROLLING BY INVITATIONPHASE2
80 participants
INTERVENTIONAL
Reykjavik, Iceland
Started: Jun 24, 2019
Completed Clinical Trials
11 completed trials for Carfilzomib in Multiple Myeloma
Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
NCT00511238COMPLETEDPHASE2
312 participants
INTERVENTIONAL
Mobile, United States +33 more
Started: Aug 1, 2007
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
NCT01775553COMPLETEDPHASE2
13 participants
INTERVENTIONAL
New York, United States
Started: Sep 1, 2013
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
NCT01351623COMPLETEDPHASE2
44 participants
INTERVENTIONAL
New York, United States
Started: May 9, 2011
Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
NCT02302495COMPLETEDPHASE2
32 participants
INTERVENTIONAL
Avignon, France +32 more
Started: Jan 8, 2014
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
NCT00530816COMPLETEDPHASE2
164 participants
INTERVENTIONAL
Scottsdale, United States +29 more
Started: Sep 1, 2007
Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma
NCT02056756COMPLETEDPHASE1, PHASE2
63 participants
INTERVENTIONAL
Kiel, Germany +2 more
Started: Apr 1, 2014
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
NCT02412878COMPLETEDPHASE3
478 participants
INTERVENTIONAL
Scottsdale, United States +139 more
Started: Sep 9, 2015
Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
NCT01496118COMPLETEDPHASE1, PHASE2
80 participants
INTERVENTIONAL
Denver, United States +12 more
Started: Dec 1, 2011
A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
NCT01677858COMPLETEDPHASE1, PHASE2
116 participants
INTERVENTIONAL
Tucson, United States +34 more
Started: Jul 4, 2012
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
NCT01980589COMPLETEDPHASE1
22 participants
INTERVENTIONAL
Encinitas, United States +8 more
Started: Aug 1, 2013
Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients
NCT04065789COMPLETEDPHASE2
41 participants
INTERVENTIONAL
Afula, Israel +13 more
Started: May 2, 2018
Showing 20 of 220 total trials